TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02651441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-CIK
Description: 8×10\^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
Study: NCT01188746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire
Description: Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
Study: NCT02771015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border®
Description: randomization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cosmopor steril®
Description: randomization
Study: NCT03455166

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum Markers
Description: Serum Markers

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum Markers
Description: Serum Markers
Study: NCT01274364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JADE
Description: Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIAMOND
Description: Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
Study: NCT00534703

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: AAV1/SERCA2a
Description: AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10\^13 DRP (DNase resistant particles)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
Study: NCT04141033

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of neopterin levels
Description: neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of neopterin levels
Description: neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
Study: NCT01890239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Programme for the Last Days of Life
Description: The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
Study: NCT03659409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: 4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist - Mindfulness-Based Intervention
Description: Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
Study: NCT04060368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications
Description: Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications
Description: Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
Study: NCT02841774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 40mg daily (Weeks 2 - 14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
Study: NCT04172363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenisept and Serasept
Description: Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
Study: NCT04462263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0014242
Description: Solid suspension capsule
Study: NCT03577626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
Study: NCT04469153

Intervention type: OTHER
Intervention: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
Description: No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
Study: NCT01923077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: usual care with Simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
Study: NCT01882140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation by Capacitive Field

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrical Stimulation by Capacitive Field Placebo Sham
Study: NCT00957047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL - Part II
Description: Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
Study: NCT01271439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
Study: NCT03703063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: Administered by intravenous infusion over 30-40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: Administered by intravenous infusion over 30-40 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onivyde
Description: Administered by intravenous infusion over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onivyde
Description: Administered by intravenous infusion over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered by intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fu
Description: Administered by intravenous infusion over 46 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fu
Description: Administered by intravenous infusion over 46 hours.
Study: NCT03034226

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose clamp technique
Description: Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose clamp technique
Description: Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
Study: NCT02207231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for guselkumab
Description: Subcutaneous injections to maintain the blind.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for guselkumab
Description: Subcutaneous injections to maintain the blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for guselkumab
Description: Subcutaneous injections to maintain the blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Subcutaneous injections to maintain the blind.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for adalimumab
Description: Subcutaneous injections to maintain the blind.
Study: NCT03236766

Intervention type: OTHER
Group type: OTHER
Intervention: Citizens' panels
Description: This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
Study: NCT03929367

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Single IV administration of oxytocin
Study: NCT01150747

Intervention type: DRUG
Intervention: ceftriaxone
Description: 250mg IM once

Intervention type: DRUG
Intervention: Azithromycin
Description: 1 gm once
Study: NCT02449876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroscience Education
Description: The following topics will be discussed in the education~* Basic structure of the nervous system~* Basic physiology of the nervous system~* The function and importance of pain~* Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear.
Study: NCT00552331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plates to treat fractures of the distal femur
Description: use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LISS
Description: treatment of distal femur fractures with less invasive stabilization systems
Study: NCT02660242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Tabs
Description: Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin Reduction
Description: Basal insulin reduction to 50% 5 minutes before the start of exercise.
Study: NCT03027661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Inject 10 mL of 0.5% bupivacaine into cervical stroma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Inject 10 mL of 0.9% NaCl into cervical stroma
Study: NCT02920411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatopic Treatment Cream
Description: Applied twice a day minimum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatopic Body lotion
Description: Applied at libitum.
Study: NCT02674334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS monitored not treated
Description: Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
Study: NCT03694990

Intervention type: OTHER
Intervention: Follow-up schedule
Description: Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.

Intervention type: OTHER
Intervention: Follow-up schedule
Description: Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.

Intervention type: OTHER
Intervention: Follow-up schedule
Description: Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
Study: NCT01292161

Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: Tab 210 mg, 630 mg, daily, six months.
Study: NCT04569682

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifePort transrenal artery perfusion
Description: transrenal artery perfusion group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifePort transrenal vein perfusion
Description: transrenal vein perfusion group
Study: NCT03916952

Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walk Test
Description: The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.

Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minute Walk Test
Description: The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
Study: NCT01232270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: 1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
Study: NCT02234609

Intervention type: DEVICE
Group type: OTHER
Intervention: modified ART class IV
Description: Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
Study: NCT02931474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: Growth Hormone-Releasing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00988624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon IR Tablet
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR1
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR2
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR3
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon MR4
Description: Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
Study: NCT04172870

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular analysis
Description: RT- PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular analysis
Description: RT- PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular analysis
Description: RT- PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular analysis
Description: RT- PCR
Study: NCT04303988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: IV
Study: NCT03561142

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep regional hyperthermia
Description: Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen.
Study: NCT00881621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Capecitabine
Description: Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
Study: NCT04308577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet with added MCT
Description: The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.